Aeterna Zentaris Inc. (USA) (AEZS) Shares Up over 30% on News of Successful Clinical Investigator Meeting

Share

Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS) is currently developing a new means of evaluating adult growth hormone deficiency (AGHD), which aims to be more successful and safer to use than the alternative insulin tolerance test (ITT), which is used by most doctors today. Shares of the stock have risen significantly today after the company announced that they have successfully concluded a meeting of 77 investigators for the confirmatory Phase 3 trial of this evaluation process called Macrilen.

“On January 16, we held an Investigators’ Meeting for our multi-center confirmatory Phase 3 clinical trial of Macrilen™,” Dr. Richard Sachse, Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS) Chief Scientific Officer explained. “The purpose of the meeting was to review Macrilen™ with the investigators, as well as the clinical trial protocol. The 77 investigators and site personnel who attended the meeting included Jose Manuel Garcia, MD, PhD, Associate Professor of Medicine at University of Washington School of Medicine, Seattle, who is serving as coordinating investigator. Dr. Garcia expressed his commitment to the development of Macrilen™ because of the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD.”

If phase 3 trials go as hoped for, Macrilen could become a preferred substitute to ITT, because it is safer and doesn’t require patients to become hypoglycemic in order to work. It is also a much faster method of evaluation than ITT, and less expensive to conduct.

The stock is up 37.83% or $1.01 following the news, hitting $3.68 per share. About 900,211 shares traded hands. AEZS has risen 853.57% since June 12, 2015 and is uptrending. It has outperformed the S&P500 by 862.44%.

From a total of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS) stock, 3 rate it a “Buy”, 0 a “Sell”, and 0 a “Hold”. This means that 100% of the ratings are positive. The highest target price is $12.0 while the lowest target price is $1. The mean of all analyst targets is $11.50 which is 212.50% above today’s ($3.68) stock price. Aeterna Zentaris Inc. was the topic of 5 analyst reports since August 18, 2015 according to the firm StockzIntelligence Inc. H.C. Wainwright maintained shares on December 2 with a “Buy” rating. Canaccord Genuity upgraded AEZS stock in a recent report from November 9 to a “Buy” rating.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical firm engaged in developing treatments in oncology, endocrinology and women’s health. The company has a market cap of $36.24 million. The Firm has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. It currently has negative earnings. The Company’s drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds , which are in pre-clinical development.

#focuskw=’AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’##metadesc=’Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS) is currently developing a new means of evaluating adult growth hormone deficiency (AGHD), which aims to be more successful and safer to use than the alternative insulin tolerance test (ITT), which is used by most doctors today. Shares of the stock have risen significantly today after the company announced that they have successfully concluded a meeting of 77 investigators for the confirmatory Phase 3 trial of this evaluation process called Macrilen.

“On January 16, we held an Investigators’ Meeting for our multi-center confirmatory Phase 3 clinical trial of Macrilen™,” Dr. Richard Sachse, Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS) Chief Scientific Officer explained. “The purpose of the meeting was to review Macrilen™ with the investigators, as well as the clinical trial protocol. The 77 investigators and site personnel who attended the meeting included Jose Manuel Garcia, MD, PhD, Associate Professor of Medicine at University of Washington School of Medicine, Seattle, who is serving as coordinating investigator. Dr. Garcia expressed his commitment to the development of Macrilen™ because of the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD.”If phase 3 trials go as hoped for, Macrilen could become a preferred substitute to ITT, because it is safer and doesn’t require patients to become hypoglycemic in order to work. It is also a much faster method of evaluation than ITT, and less expensive to conduct.

‘##metarobot=’index’##newskw=’Sony Corp (ADR) news,Sony Corp (ADR) – (NYSE:SNE),NYSE:SNE Analyst rating analysis,Stock Analysis,Outlook and potential,SNE Price change and trend,SNE stock update’##sitemap=’include’##skipsocial##stockticker=’NASDAQ:AEZS’#

COMMENTS: